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Abstract
Background: The CPCRA 064 study examined the effect of structured treatment interruption (STI) of up to 4 months
followed by salvage treatment in patients failing therapy with multi-drug resistant HIV. We examined the relationship
between the reversion rate of major reverse transcriptase (RT) resistance-associated mutations and change in viral
replication capacity (RC). The dataset included 90 patients with RC and genotypic data from virus samples collected at 0
(baseline), 2 and 4 months of STI.
Principal Findings: Rapid shift towards wild-type RC was observed during the first 2 months of STI. Median RC increased
from 47.5% at baseline to 86.0% at 2 months and to 97.5% at 4 months. Between baseline and 2 months of STI, T215F had
the fastest rate of reversion (41%) and the reversion of E44D and T69D was associated with the largest changes in RC.
Among the most prevalent RT mutations, M184V had the fastest rate of reversion from baseline to 2 months (40%), and its
reversion was associated with the largest increase in RC. Most rates of reversion increased between 2 months and 4 months,
but the change in RC was more limited as it was already close to 100%. The highest frequency of concurrent reversion was
found for L100I and K103N. Mutagenesis tree models showed that M184V, when present, was overall the first mutation to
revert among all the RT mutations reported in the study.
Conclusion: Longitudinal analysis of combined phenotypic and genotypic data during STI showed a large amount of
variability in prevalence and reversion rates to wild-type codons among the RT resistance-associated mutations. The rate of
reversion of these mutations may depend on the extent of RC increase as well as the co-occurring reversion of other
mutations belonging to the same mutational pathway.
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Introduction
Treatment Interruptions (TI) can occur in clinical practice due
to drug toxicity, patient non-adherence and antiretroviral
treatment (ART) fatigue. In the setting of multi-drug resistant
(MDR) viremia, the prevailing concept is that during treatment
interruption, the MDR strain is rapidly overgrown by wild-type
virus at higher HIV-1 RNA levels [1], associated with reversion of
resistance mutations to wild-type codons, a shift toward pheno-
typic drug susceptibility, and an increase in viral replicative
capacity, leading to the restoration of sensitivity to antiretroviral
drugs [1]. With the re-introduction of ART, resistant strains
genotypically similar to baseline virus may emerge [2,3].
Currently, in clinics with ready access to the more recently
approved antiretrovirals, the number of individuals with treatment
associated viremia and multi-drug resistance is declining [4].
Further, treatment interruptions as therapeutic strategies have
fallen out of favor because of the accelerated loss of CD4+ cells
and nonHIV adverse events [5,6]. However, there are a number
of reasons to continue to explore TI in the setting of MDR. Firstly,
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14638despite the availability of newer therapies, there are concerns that
the pipeline for future anti-HIV drug development has diminished.
As a consequence, individuals with MDR in today’s clinic may
have few treatment options and for these individuals it is important
to continue to explore alternative treatment strategies. Further, in
resource limited settings, there may be few antiretroviral options,
in which case maintaining therapy in the setting of drug resistance
may be unavoidable. Also, transmitted drug resistance is of
concern in both the adult patient and in the setting of mother to
child prophylaxis (particularly in more resource limited settings).
TI studies may provide a relevant perspective on the loss of
mutations for individuals with transmitted drug resistance [7,8].
Clinical outcomes in patients undergoing structured treatment
interruption (STI), in which treatment is withdrawn for a fixed
time period, have been described in a number of studies. However,
the extent of reported genotypic changes during STI differs
between studies, and only a few of these studies described the
patterns of reversion of mutations to wild-type codons, which
occur as a combination of re-emergence of preexisting variants
with fewer resistance mutations and actual reversion of codons
within a viral genome. An early study reported that almost all
patients showed complete genotypic and phenotypic reversion of
the dominant viral strain from multi-drug resistant to wild-type
virus [1]. Longitudinal analysis of drug resistance in these samples
showed that changes in the dominant viral strain occurred at
various times, generally abruptly rather than progressively.
Interestingly, fewer genotypic changes during STI were reported
in a second study [3], as only 5 patients out of 18 showed complete
reversion of mutations based on standard population-based
sequences, suggesting inter-patient differences in the potential of
reversion of dominant viral strains. Devereux et al [9] measured
the decline of detectability of protease (PR) and reverse
transcriptase (RT) resistance associated mutations in patients
stopping therapy for varying durations of time. The authors
reported a faster rate of reversion for primary resistance mutations
(K70R, M184I/V, T215Y/F in RT, and D30N, M46I/L, V82A,
L90M in PR) compared to secondary mutations (M41L, D67N,
T69D/N, L210W, K219Q/E in RT and L10I/V, L63P, A71V/
T, V77I in PR). Similarly, a stepwise pattern of reversion of
resistance associated mutations (RAMs) to wild-type was described
in one multi-drug resistant HIV-positive individual by compara-
tive analyses of longitudinal population-based sequences [10]. A
mixture of the mutant V and the wild-type variant M at amino
acid 184 in RT was first detected in the MDR patient followed by
complete reversion to the wild-type amino acid at this position.
Mixtures of wild-type and variants T215Y in RT, L10F, I54V and
V82A in PR appeared 6 months after the first mixture at position
184 was detected. Together, these studies suggest the possible co-
existence of mechanisms of back-reversion and outgrowth of wild-
type variants during STI, where the prevalence of the mutant
viruses depends on virus fitness gain and other host factors.
Resistance mutations have been shown to accumulate in a
specific order [11], but little is known about the dynamics of
reversion to wild-type population. The CPCRA 064 study, the
largest published randomized trial of STI in patients with MDR
HIV-1, demonstrated that STI was not associated with virologic
benefit but instead had a prolonged negative impact on CD4
counts [12,13]. Changes in genotypic patterns were observed in
the majority of individuals during STI, although some patients
showed only partial or no shift in their viral population. The aim
of this study was to describe the mechanisms of reversion of RT
mutations to wild-type viral population during STI and the
relationship with replication capacity (RC) as a measure of fitness.
Using the longitudinal data collected at baseline, 2 months and 4
months of STI in the CPCRA 064 study, we will describe the
patterns of loss of resistance-associated mutations and emergence
of wild-type (WT) virus. We will identify early/late reverting
mutations, linkage between mutations, and the impact of the
reversion on viral RC, in an attempt to identify inter-patient
differences in the rate of reversion to wild-type viral population.
Materials and Methods
Study dataset
The CPCRA 064 study examined the effect of 4 months of STI
followed by salvage treatment in patients failing therapy with
multi-drug resistant HIV. This study was approved by the
institutional review board at all participating sites and all patients
had written informed consent. Details regarding the study design
of this trial and the list of all participating sites are described
elsewhere [12,13]. Of the 274 patients enrolled in the trial, 140
were randomized to the STI arm. 122 of those patients had
sufficient sample available for retrospective replication capacity
testing. Information regarding mutation score and replication
capacity was collected at 0 (baseline), 2, and 4 months of STI. Not
all patients were able to tolerate 4 months of STI; 32 patients
resumed treatment before the end of the 4 month STI. This
analysis was performed on the 90 patients who were able to sustain
the 4 month STI. Among those 90 patients, 6 patients were further
excluded from the mutation reversion analyses due to missing
genotypic data at one of the 3 timepoints.
Phenotypic and genotypic data
Viral replication capacity (RC) was retrospectively determined
using a modified PhenoSenseH HIV assay (Monogram Bioscienc-
es, South San Francisco). RC values were expressed as a
percentage of NL4-3 drug-sensitive reference and adjusted so that
the median value of wild-type viruses approximated 100%.
Genotyping for the clinical trial was performed using the
TruGeneH 4.0 assay (Visible Genetics, Inc.). In the TruGeneH
assay, a 1.3-kb sequence from the pol region encompassing the
entire protease gene and the first 250 amino acids of the reverse-
transcriptase gene is generated by bidirectional automated
sequencing on the Microgene Clipper (Siemens Diagnostics,
Inc.). HIV-1 drug resistance mutations were identified using the
October 2004 International AIDS Society definition [14].
Genotypic data consisted of the binary-coded presence/absence
of 54 mutations in the reverse transcriptase (RT) and protease (PR)
genes. Mutations present in fewer than 10% of the samples at
baseline were not considered in the reversion rate and tree
analyses. The final list of mutations included M41L, E44D, D67N,
T69D, K70R, L74V, L100I, K103N, V108I, V118I, Y181C,
M184V, G190A, L210W, T215F, T215Y and K219Q in RT; and
L33F, L33I, M46I, M46L, G48V, V82A, V82F, V82L, V82S,
I84A, I84C, L90M in PR.
Statistical analyses
The significance of changes in RC over time was tested by
Jonckheere-Terpstra trend test and Wilcoxon signed-rank test for
paired samples. The rate of reversion of a mutation was estimated
as the percentage of patients with a mutation reverting between 2
timepoints. The reversion rate was calculated from a subset of 84
patients who sustained the STI for at least 4 months and for whom
genotypic data was available at baseline, 2 and 4 months.
Concurrent reversion rate between two given mutations was
calculated as the rate of simultaneous reversion of these 2
mutations between 2 consecutive timepoints (Equation 1). This
co-reversion value was used as a marker of potential linkage
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The order of reverting mutations was examined using
mutagenetic tree models [15]. In our case of reversion events,
tree vertices represent a reversion at a specific codon and edges are
associated with the conditional probability that a reversion will
occur, given that the ancestor in the tree has occurred. These
models require non-reversibility of genetic events, which is verified
in this dataset as none of the mutations changed back to a variant
form from the wild-type sequence over the course of the STI. We
used the software package Mtreemix [16].
Results
RC change during STI
Viral RC increased during the duration of STI. Between
baseline and 2 months, median RC increased from 47.5%
(IQR=21.0%-70.5%) to 86.0% (49.0%-104.8%). At 4 months,
median RC had increased to 97.5% (IQR=75.3%-121.8%)
(Figure 1-A). The overall positive trend was significant (p-value
,2.2e-16). The increase in RC was greater during the first 2
months than during the second half of STI (p-values of 4.315e-11
and 0.01073 respectively) (Figure 1-B). It ranged from –50 to 170
between baseline and 2 months, and from –87 to 135 between 2
and 4 months.). These results were consistent with the emergence
of a different viral population with greater ability to replicate in the
absence of drugs over the course of the STI. The change in viral
RC (DRC) during STI varied amongst patient samples. Few of the
patients able to sustain 4 months of STI (14.4%) showed a
decrease in RC during these time intervals. Inter-patient
variability suggested the impact of non-viral factors; therefore we
examined the effect of CD4+ cell count at baseline on subsequent
viral phenotype.
Patients were grouped based on their baseline CD4: CD4,100
cells/mm
3 (lowCD4BL, n=37), 100#CD4,300 (medCD4BL,
n=29), CD4$300 (highCD4BL, n=24). All 3 groups showed an
increase in median RC (Figure 1-C). However, the extent of RC
increase was significantly smaller in lowCD4BL (median DRC
=18 from baseline to 4 months) than in the other groups. In
medCD4BL, median DRC =63.5 (p-value=0.019) and median
DRC=57 (p-value=0.004) for highCD4BL.
Resistance mutation prevalence and reversion rate
All patients included in this study exhibited multiple resistance
mutationsat baselinewitha mediannumberofmutationsof7 and 3
forRTand PR, respectively. Thenumber ofmutationsdecreasedto
a median number of 2 RT mutations and 0 PR mutation during the
STI. Over the course of the STI, we observed a shift in the
distribution of the number of mutations by patient. The proportion
of viruses with high number of mutations decreased progressively,
while the proportion of viruses with lower number of mutations
increased, indicating a continuum of mutation reversion rates. At 4
months, some patients still carried MDR viruses. To examine the
impact of host factors on the ability of viruses with few mutations to
grow, we analyzed the reversion rates of RT mutations within the 3
CD4 baseline groups. In lowCD4BL, we observed significantly
fewer reversions than in the medCD4BL and highCD4BL groups
(Figure 2). The median proportion of RT mutations reverting were
9.5% in lowCD4BL and 75% in the 2 other groups (Kruskal-Wallis
rank sum test, p=0.02).
The most prevalent mutations at baseline were M41L (73.8% of
patients), M184V, and T215Y (69%, 66.7% respectively). Among
those 3 mutations, M184V had the fastest rate of reversion with
Figure 1. Change in Replication Capacity (RC) during 4 months of structured treatment interruption (STI). Panel A: Distri-
bution of Replication Capacity of the patient virus at baseline (BL), 2 months and 4 months of STI. The increasing trend is significant (trend test
p-value ,11 0
-15). Panel B: Distribution of RC change by time intervals (between baseline and 2 months of STI, and between 2 months and 4 months
of STI). The decrease in RC changes over time shows that most changes in RC happen between baseline and 2 months. The wide range of individual
values shows inter-patient variability in the reversion to wild-type. Panel C: RC change by baseline CD4 strata. The 3 groups were defined as baseline
CD4 counts ,100 cells/mm
3 (lowCD4BL), 100#CD4,300 (medCD4BL), and CD4$300 (highCD4BL). Median RC change during 4 months of STI was 18
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after 2 months of STI. In comparison, M41L and T215Y had a rate
of reversion of 32% and 23% respectively within the same time
period. Of all mutations studied, T215F showed the fastest reversion
rate between baseline and 2 months, with 41% of the patients
reversing this mutation (Table 1). Mutation reversion continued
between 2 and 4 months within the STI. The rate of back-shifting of
most mutations increased over time. More than 50% of the patients
who still had M184V and L74V at 2 months saw an outgrowth of
variants without those mutations. The rate of reversion of Y181C
increased from 9% to 33%. The emergence of viral strains without
the mutation slowed down for other mutations, such as L210W,
which reverted in 22% of the samples between baseline and 2
months, and in 14% between 2 and 4 months. Notably, the mutation
K103N had a high rate of reversion at both timepoints, with a
reversion rate of 62% over the duration of the STI.
To examine the potential genomic linkage of reversion of pairs of
mutations, we calculated the frequency of pairs of RT mutations
reverting concurrently between baseline and 2 months of STI. The
frequency distribution ranged from 0 (no linkage) to 1 (high linkage)
with a median of 0.34, 80th and 90th percentiles of 0.65 and 0.82
respectively (Table S1). The highest frequency of concurrent
reversion was found for L100I and K103N. The loss of M41L
was most closely associated with the loss of several mutations,
including L210W (0.96), T215Y (0.91), T69D (0.89) and V118I
(0.78). The mutation M184V was most likely to revert concurrently
with E44D, T69D, L210W and T215Y. The reversion of mutations
D67N and T215F was associated with K219Q.
Pathway of resistance mutation reversion and change in
RC
We generated mutagenetic tree models to derive the order of
reversion of RT mutations. Patients in lowCD4BL were excluded
as they showed limited reversion during STI. The optimal number
Figure 2. RT reversion rate by baseline CD4 strata. The reversion
rate was calculated as the proportion of RT mutations reverting to wild-
type codon divided by the number of RT mutations at baseline for each
patient. Patients with lower CD4+ cell count at baseline (CD4,100)
showed fewer reversion of RT mutations, the median proportion of RT
mutations reverting for this group was 9.5%, compared to over 75% in
the other groups.
doi:10.1371/journal.pone.0014638.g002
Table 1. Prevalence and rate of reversion of RT mutations at baseline (BL), 2 months (2mo) and 4 months (4mo) Structured
















E44D 26.2 22.6 22.6 14 5 18.2 90
T69D 21.4 16.7 14.3 22 14 33.3 76
108I 21.4 16.7 8.3 28 46 61.1 58
181C 39.3 36.9 28.6 9 33 39.4 57
184V 69.0 41.7 19 40 57 74.1 53.5
67N 57.1 42.9 31 27 26 45.8 51.25
219Q 17.9 15.5 8.3 20 50 60.0 50
118I 41.7 29.8 25 29 24 42.9 48
103N 53.6 36.9 21.4 36 41 62.2 45
215F 26.2 15.5 10.7 41 38 63.6 41
70R 22.6 21.4 14.3 32 46 63.2 39.75
41L 73.8 51.2 38.1 32 29 50.0 36
215Y 66.7 52.4 38.1 23 30 44.6 34
210W 54.8 44 36.9 22 14 32.6 30
74V 34.5 22.6 11.9 34 58 72.4 29
100I 14.3 11.9 6 17 50 58.3 16.8
190A 21.4 20.2 14.3 11 38 44.4 15.55
a: RC gain was defined as the difference in median RC between the viruses who showed the reversion of a givenmutation and the viruses who kept the mutation between
baseline and 2 months STI.
The prevalence of each mutation decreased over the course of the STI. The last column of the table represents the difference between the median DRC of the samples
which reverted a mutation back to wild-type codon and the median DRC of the samples which did not revert the mutation. Most mutation reversions were associated
with an increase in RC over the course of the STI. The largest increase in RC occurred between baseline and 2 months of STI. Between 2 months and 4 months of STI, the
reversion of mutations was also associated with an increase in RC, although of a lesser magnitude since RC was already close to 100% at 2 months (data not shown).
doi:10.1371/journal.pone.0014638.t001
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cross- validation. The resulting model comprised 2 components, a
star-shaped tree representing the noise component and another
tree with 2 branches (Figure 3 and Figure S1). In this latter tree,
M184V was found to be the first mutation to revert. The tree
separated into two branches, one branch supported by M41L,
T215Y and L210W, another branch containing K103N, T215F
and K219Q. The branches were supported by bootstrap analysis.
To examine whether the order of reversion during STI was
related to an optimized benefit in viral RC, we compared the DRC
in viruses losing or retaining a given mutation. Although all
reversions were associated with increase in RC, the extent of DRC
was variable (Table 1, Figure 4-A). Among the most prevalent
mutations, reversion of M184V was associated with the largest
DRC. Other mutations that were less frequent but associated with
a large increase in RC included E44D, T69D, D67N, and 2 Non-
Nucleoside RT inhibitors (NNRTI) mutations (namely V108I and
Y181C). Interestingly, the potential extent of DRC was associated
with baseline RC. Viruses with low baseline RC showed a larger
spread of DRC than viruses with higher baseline RC values.
Figure 4-B shows the association between baseline RC and RC
change after 2 months of STI for the mutation M184V. Viruses
that reverted M184V between baseline and 2 months of STI and
with baseline RC below 50% showed a median RC change of 82%
(IQR=55% - 108.7%), while viruses with baseline RC above 50%
showed a median RC change of 39.5% (IQR=21.5% - 46.7). The
correlation was significant with p-value=0.025.
Discussion
Antiretroviral treatment interruption is a common occurrence
in clinical practice during which the restoration of viral sensitivity
to antiretroviral drugs has been observed as a consequence of the
outgrowth of virus strains with fewer or no resistance mutations.
The present study aims to characterize the evolutionary patterns of
the reversion of resistance mutations during treatment interrup-
tion. We used data collected during the duration of STI in the
CPCRA 064 study for our analyses. Viral RC increased during the
4 months of STI, increasing more dramatically during the first 2
months than during the second half of the STI. The extent of RC
increase was smaller in patients with low baseline CD4 cell count
(CD4,100).
Our analyses showed a large variability in the pattern and rate
of genotypic reversion to drug sensitivity among patients. After 4
months of STI, only 33% of the patients had reached a complete
reversion to wild-type codons. The total number of mutations
reverting during the STI depended on the number of mutations at
baseline as well as the baseline CD4. The observation that a higher
mutation reversion rate was observed in patients with higher
baseline CD4 was consistent with previous findings [1], and may
reflect the fact that a larger pool of wild-type integrated proviruses
might be expected in this situation, representing prior circulating
forms of HIV that were dominant before the institution of ART.
Figure 3. Mixture of mutagenetic trees obtained for the
reversion of RT mutations. This mutagenetic tree model describes
the patterns of reversion of mutations in patients with CD4+ cell count
.100 at baseline. The model comprised two components: one tree
representing the estimated the order of reversion of the RT mutations
during the structured treatment interruption, and one star-like tree,
with equal weight for each mutation, representing the noise in the
model (Figure S1). The numbers at the top of each tree represent the
weight of each tree component in the model, and numbers on the
edges of the tree represent the conditional probability of the events.
doi:10.1371/journal.pone.0014638.g003
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reversion as compared to those with higher CD4 counts, with
some viruses presenting a complete (or near complete) disappear-
ance of resistance mutations, whereas other viruses showed no
change at all.
Interestingly, baseline RC was not predictive of the likelihood of
reversion to wild-type HIV (data not shown). At the end of the 4
month STI, 16 of the 90 patients (17.8%) who maintained the STI
for 4 months had no reversion of their mutations. This subset of 16
patients had lower CD4+ cell count at baseline (median CD4/
mm
3 =58) and less reduction of CD4 during STI. They were also
characterized by little change in viral RC and viral load (data not
shown). These observations are generally characteristic of more
advanced disease, possibly having longer exposure to prior ART.
Once again, the lack of reversion in this subset may be explained
by low levels of wild-type viruses in latently infected CD4 cells and
an exhausted immunological potential for recovery. A prolonged
period of STI might be required for the original wild-type virus to
re-emerge in the circulating plasma viral population.
Our data analyses showed a large amount of variability in
prevalence and reversion rates to wild-type codons among the
resistance-associated mutations (RAMs). We observed that con-
trary to expectations, mutations do not appear to shift concur-
rently. The mutagenesis tree models showed that M184V, when
present, was overall the first mutation to revert among all the RT
mutations reported in this study. Our analyses suggested that the
rank of M184V in the model may be explained by its high
prevalence and the large increase in viral RC associated with its
reversion. Moreover, there is no evidence that M184V co- reverts
with any particular RT resistance mutation. This result is
consistent with the findings from a recent study from Hedskog et
al. where ultra-deep pyrosequencing was used to analyze in more
detail the genotypic composition at specific RT positions of
longitudinal samples from 6 patients [17].
Following M184V, the model of reversion divides in two branches,
one consisting of M41L, T215Y and L210W (branch 1) and the other
branch consisting of K103N, K219Q and other RT mutations
(branch2).In branch1, M41L, T215Y and L210Whave beenshown
t op r e f e r a b l yc l u s t e rt o g e t h e rr a t h e rt h a nw i t ho t h e rm e m b e r so ft h e
thymidine analog resistance mutation (TAM) pathway and to have a
large impact on viral fitness [18]. This may explain why they are
more likely to co-revert together as well. Branch 2 grouped other
TAM mutations and NNRTI resistance mutations. Interestingly, the
mutation at position 103 in RT, which is not reported to revert easily
[19], did revert in our study. This is most likely due to mutation
linkage, since K103N had high co-reversion frequency with other
mutations such as M184V and L100I.
Our results are consistent with previous observations that the
loss of drug resistance mutations may occur as a consequence of
emerging wild-type virus and the reversion or back mutation to a
more fit state [1,20]. Using a survival analysis model, Trignetti et
al. did not find a pattern in the reversion of RT mutations during
treatment interruption [21]. The difference in results may be due
to the nature of the cohort data. The cohort they used was
comprised of patients with varied durations of treatment
interruption. We used predefined timepoints in controlled clinical
settings that allow for the linking of genotype data with viral fitness
at fixed time of the reversion process within the cohort.
Our analyses were performed on a subset of patients from the
CPCRA 064 cohort who were able to sustain the STI for at least 4
months. However, some patients were not able to tolerate long
period of treatment interruption [13]. A total of 32 patients
resumed ART before the end of the 4 months STI. These patients
had similar CD4+ count, RC and resistance mutations prevalence
at baseline as our subset, but higher HIV RNA levels at baseline
(5.4 log copies/ml vs. 4.9 log copies/ml, p,0.0001). These
patients showed faster rate of reversion of RT resistance mutations
during the STI compared to the subset used in our analyses
(although only Y181C and G190A were significantly faster, data
not shown), and a higher median RC after 2 months STI
(p=0.002), suggesting the effect of other immunological and
clinical factors on viral rebound. Moreover, our analysis was
limited to RT resistance mutations. More analysis, including
protease inhibitors resistance mutations, is needed to fully
understand the underlying mechanisms of reversion of multi-drug
resistant HIV in the absence of drug pressure.
Figure 4. Replication Capacity (RC) gain associated with the reversion of RT resistance mutations. Panel A: Median RC gain for individual
RT mutation. The RC gain is calculated as the difference in RC between the viruses which showed the reversion of a given mutation and the viruses
who kept the mutation. Panel B: RC change in viruses reverting M184V to wild-type between baseline and 2 months of Structured Treatment
Interruption. The RC change is calculated as the difference in RC between baseline and 2 month for each virus showing M184V at baseline. The RC
change is plotted against baseline RC to show the association between baseline RC and RC change after 2 months of STI.
doi:10.1371/journal.pone.0014638.g004
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to explore the genotypic changes occurring during STI and the
corresponding effect on viral RC. Much inter- patient variability is
observed with regard to the loss of resistance-associated mutations
and the emergence of wild-type virus. The reversion of resistance
mutations to wild-type codons appears to follow a predefined
pattern, based on the prevalence of RAMs and mutation linkage.
Using mutagenetic tree models, we found that in this dataset,
M184V was the most prevalent mutation and the first to change,
followed by the M41L, T215Y pathway or the K103N, K219Q
pathway. These similarities between the pathways of acquisition
and reversion of RAMs suggest the importance of compensatory
effects between mutations. Reversion of M184V was associated
with large increases in viral RC, but RC alone cannot explain that
M184V reverts first, since other secondary mutations were also
associated with large RC changes. The extent of viral RC increase
during the STI is variable among patients, and seems to be
impacted by other clinical factors, such as baseline CD4. More
research is needed to understand fully the mechanisms of reversion
to wild-type off therapy.
Supporting Information
Table S1 Frequency of concurrent reversion for RT mutations.
Each column of the table lists the frequency of concurrent
reversion for a given mutation paired with the mutation listed in
rows. The frequencies range from 0 (or NA when 2 mutations do
not coexist) to 1. Mutations belonging to the same pathway of
reversion appear more likely to revert at the same time.
Found at: doi:10.1371/journal.pone.0014638.s001 (0.08 MB
DOC)
Figure S1 Star-like mutagenetic tree obtained for the reversion
of RT mutations. This tree represents the noise component in the
mixture of mutagenetic trees model describing the patterns of
reversion of mutations in subjects with CD4+ cell count .100 at
baseline. The numbers at the top of each tree represent the weight
of each tree component in the model, and numbers on the edges of
the tree represent the conditional probability of the events.
Found at: doi:10.1371/journal.pone.0014638.s002 (0.10 MB TIF)
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